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Abstract
Background: The hypothesis of this study was that local anesthesia with monitored anesthesia care (MAC) is
not harmful in comparison to general anesthesia (GA) for patients undergoing Transcatheter Aortic Valve
Implantation (TAVR).
TAVR is a rapidly spreading treatment option for severe aortic valve stenosis. Traditionally, in most centers, this
procedure is done under GA, but more recently procedures with MAC have been reported.
Methods: This is a systematic review and meta-analysis comparing MAC versus GA in patients undergoing
transfemoral TAVR. Trials were identified through a literature search covering publications from 1 January 2005
through 31 January 2013. The main outcomes of interest of this literature meta-analysis were 30-day overall
mortality, cardiac-/procedure-related mortality, stroke, myocardial infarction, sepsis, acute kidney injury, procedure
time and duration of hospital stay. A random effects model was used to calculate the pooled relative risks (RR) with
95% confidence intervals.
Results: Seven observational studies and a total of 1,542 patients were included in this analysis. None of the studies
were randomized. Compared to GA, MAC was associated with a shorter hospital stay (−3.0 days (−5.0 to −1.0);
P= 0.004) and a shorter procedure time (MD −36.3 minutes (−58.0 to −15.0 minutes); P <0.001). Overall 30-day
mortality was not significantly different between MAC and GA (RR 0.77 (0.38 to 1.56); P = 0.460), also cardiac- and
procedure-related mortality was similar between both groups (RR 0.90 (0.34 to 2.39); P = 0.830).
Conclusion: These data did not show a significant difference in short-term outcomes for MAC or GA in TAVR. MAC
may be associated with reduced procedural time and shorter hospital stay. Now randomized trials are needed for
further evaluation of MAC in the setting of TAVR.
Keywords: TAVR, Local anesthesia, General anesthesia, Aortic stenosis
Background
Transcatheter Aortic Valve Implantation (TAVR) is a
rapidly evolving procedure for patients with severe aortic
stenosis. TAVR was initially designed as a less invasive
technique for patients who were unsuitable or at high
risk for conventional valve surgery [1,2]. With emerging
new valve technologies and improving operator experi-
ence, TAVR is likely to become an alternative option for
patients at intermediate risk in the near future. In 2009,
4,498 patients underwent TAVR in Europe and the num-
bers were rapidly growing to 18,372 in 2011 [1,3]. In
Germany, for example, TAVR is now used for approxi-
mately 50% of patients ≥75 years of age [4]. Currently,
the vast majority of TAVR procedures are performed
under general anesthesia (GA). GA is usually provided
by an anesthetist experienced in managing patients un-
dergoing conventional cardiac surgery. There are consi-
derable regional differences, with nearly 100% of cases
done under GA in the US, >80% in the UK and 66% in
France [3,5]. Initial small observational studies suggested
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and safe [6,7]. MAC was defined as cardiovascular and
respiratory monitoring of the patient by a qualified
anesthesiologist who may or may not be administering
concomitant sedation. For endovascular aortic aneurysm
repair, MAC has proven to be beneficial in a large popu-
lation of high risk patients [8]. Therefore, the impact of
MAC versus GA on outcomes for other interventional
endovascular procedures, such as TAVR, which are cur-
rently performed predominantly under GA, should also
be assessed. It is well known that GA and, in particular,
mechanical ventilation may be complicated by pneu-
monia, hemodynamic compromise and the need for
extensive catecholamine use [9,10]. Further, prolonged
intensive care or in-hospital stays are associated with
increased risk of nosocomial infections and mortality
[11]. This study intended to test the hypothesis that
MAC is equally safe as GA for TAVR.
Methods
The study was performed according to the preferred re-
porting items for systematic reviews and meta-analyses
(PRISMA) guidelines for meta-analyses (Additional file 1)
[12,13]. Planning and study design were done by two
authors (GF, PM) including creation of an electronic
database with variables of interest. The main outcome
variables of interest and search strategy (databases,
sources for unpublished data) were defined in a strategy
outline.
Search strategy
We searched EMBASE, PubMed, MEDLINE, BIOS and
ISI Web of Science for manuscripts published from 1
January 2005 through 31 January 2013. In addition, ab-
stract lists and conference proceedings from the 2006 to
2012 scientific meetings of the American College of
Cardiology, the European Society of Cardiology, the Sym-
posium on Transcatheter Cardiovascular Therapeutics,
the American Heart Association, and the World Congress
of Cardiology were searched. We also considered pub-
lished review articles, editorials and internet-based sources
of information [14-18] to assess potential information on
studies of interest. Reference lists of selected articles were
reviewed for other potentially relevant citations. No lan-
guage restriction was applied. The detailed search syntax
for the database Medline is shown in Additional file 2.
The syntax for other databases was similar but was adap-
ted where necessary. In the absence of any prospective
randomized studies, only non-randomized observational
studies could be included.
Study selection
In a two-step selection process, the titles and abstracts
of all citations were reviewed independently by two re-
searchers (PM, GF) to identify potentially relevant studies.
In a second step, the corresponding publications were
reviewed in full text to assess if studies met the following
inclusion criteria: MAC for TAVR procedures and a GA
control group (Figure 1).
Data extraction
Relevant information from the articles, including base-
line clinical characteristics of the study population and
outcome measures, were extracted using the prepared
standardized extraction database; we focused on un-
adjusted and observed outcomes.
Outcome measures
Baseline variables and clinical and angiographic data
were extracted and compared. Main outcome variables
Stage 1: Review of title 
and abstract
Stage 2: Full text review/ 
contacting study authors
81 potentially relevant 
studies identified through database searching
Excluded
N = 73 (reviews, 
editorials, case control studies)
15 potentially relevant 
studies identified through other sources 
(cross-references, conference proceedings)
91 study abstracts screened after removing 
dupicates
18 studies evaluate effects of LA versus GA 
for TAVI
Excluded n = 8
Reviews, editorials
7 studies finally included
Figure 1 Flow chart of study selection process.
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dure-related mortality, in-hospital or procedure-related
complications, stroke, myocardial infarction, vascular
complications, procedural success, acute kidney injury,
procedural time and in-hospital stay. The endpoint defini-
tions are described in Additional file 3.
Data synthesis and analysis
Data analysis was performed on an intention-to-treat
analysis, that is, patients who converted from one ap-
proach to the other (MAC to GA) during the procedure
were considered to be in the group they were originally
assigned to. Data of the selected non-randomized obser-
vational studies were combined to estimate the pooled
effect (risk ratio, RR) of local versus GA. Calculations
were based on a DerSirmonian and Laird random-effects
model, using an asymptomatic approach [19]. This mo-
del assumes that the true effects vary between studies
for unknown reasons. The primary summary measure
usually reported is the estimated average effect across
studies [20]. Continuity correction was used when no
event occurred in one group to allow calculation of a RR
[21]. Heterogeneity among trials was quantified with
Higgins’ and Thompson’sI
2 [22]. I
2 can be interpreted as
the percentage of variability due to heterogeneity bet-
ween studies rather than sampling error. An I
2>50%
was considered as at least moderate heterogeneity. Weigh-
ted average incidence of events was calculated based on a
random-effect analysis using a Freeman-Tukey double
arcsine transformation and the inverse variance method
[23]. We present our primary result estimates of the aver-
age effect across studies with 95% confidence intervals in
brackets. We did not test for publication bias or small
study effects due to the small number of studies included
in this analysis. We have performed a sensitivity analysis
excluding “gray literature” data (not yet published in peer-
reviewed literature). We also performed the analyses with
an exact permutation test for meta-analyses. All ana-
lyses were performed with “R”, version 2.15.1 (packages
“meta”, “metafor”) R Foundation for Statistical Compu-
ting, Vienna, Austria.
Results
Description of included studies and baseline
characteristics
A total of 79 articles were reviewed and 7 studies, in-
cluding 1,542 patients, satisfied the predetermined inclu-
sion criteria (Figure 1) [5-7,24-27]. Studies using only
general anesthesia or only MAC were not considered.
All studies used either a transfemoral or transaxillary ap-
proach for TAVR. Additional file 4 shows the valve types
used: three studies used predominantly or exclusively the
CoreValve (Medtronic, Minneapolis, MN, USA) [5,7,24],
three studies used predominantly the Edwards SAPIEN or
SAPIEN XT valves (Edwards Lifesciences, Irvine, CA,
USA) [6,25,26], one study did not describe which valve
type was used [27]. Table 1 shows the baseline characteris-
tics in the different studies. In two studies, the overall risk
scores (logistic EuroSCORE and/or Society of Thoracic
Surgeons (STS) score where higher for the GA group
[7,27], in one study, the risk score was significantly higher
for MAC [25], while the remaining studies did not find
a statistically significant difference (Table 1). Additional
file 5 describes the decision-making process regarding
Table 1 Differences in baseline characteristics between MAC and GA
Study Yamamoto Motloch Dhedin Ben-Dor Behan Linke Covello
MA GA MAC GA MAC GA MAC GA MAC GA MAC GA MAC GA
n 130 44 41 33 34 91 42 27 9 3 547 449 42 27
Logistic EuroScore 22.0* 26.6* NA NA 23.6 24 40.1* 28.1* 21.8 22.9 ** ** 27.3 22.9
STS score (mortality) 11.2 14.3 20.8 16.5 9.2* 14* NA NA NA NA NA NA NA NA
Prior CVA/TIA 10.1% 11.1% 14.6% 24.2% 12% 11% 30%* 9.1%* 11% 33% NA NA 19% 15%
CAD 10.1% 11.1% 43.9% 42.4% 44% 52% 55.7% 45.5% NA NA ** ** 57% 44%
Renal dysfunction (CrCl >60 ml/minute) 68.5% 63.6% NA NA 56% 44% 37.1% 50% 11% 0% NA NA NA NA
Age 83.7 84.7 82.6 83.4 83.5 83 84.1 83.7 80 83 ** ** 79.5 77.6
Females 60.5% 53.3% 65.9% 45.5% 47% 50% 58.5% 63.6% 33% 33% ** ** NA NA
Diabetes 25.6% 13.3% 29.3% 27.3% 23% 19% 30% 31.8% NA NA ** ** 33% 30%
Hypertension 81.4% 73.3% 82.5% 75.8% 74% 64% 90% 95.5% NA NA NA NA NA NA
COPD 23.3% 24.4% 9.8% 12.1% 15% 30% 14.3% 9.1% 33% 33% NA NA 69% 37%
EF 50.4%* 45.1%* 53.6% 54.8% 57% 50% 52.7% 55.2% NA NA NA NA NA NA
AVA (cm
2) 0.67 0.72 0.6 0.6 0.42 0.38 0.63 0.65 NA NA NA NA NA NA
A, not available; AVA aortic valve area, CAD coronary artery disease, COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular accident/transient
ischemic attack; EF ejection fraction, GA, general anesthesia; MAC, monitored anesthesia care; STS, Society of Thoracic Surgeons score; *significant.
**No statistically significant difference according to authors, numbers not available.
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randomized.
Overall mortality
The average 30-day mortality rate was 4.2% (1.5 to 9.2%)
in the MAC group and 5.4% (1.1 to 11.7%) in the GA
group. This difference was not statistically different be-
tween the groups (RR 0.77 (0.38 to 1.56); P= 0.460)
(Figure 2).
The cardiac and procedure-related mortality was not
significantly different either (RR 0.90 (0.34 to 2.39); P=
0.830) (Additional file 6).
Procedural outcomes
The conversion rate from MAC to GA was 6.3% (2.8 to
10.6%) or 18 out of 251 patients (Figure 3). Additional
file 7 describes the reasons for the switch.
Vascular complications were observed in 8.4% (4.8 to
12.8%) or 18 out of 205 patients in the MAC group and
in 15.6% (5.8 to 28.5%) or 31 out of 168 patients in the
GA group. However, the difference was not statistically
significant (RR 0.66 (0.35 to 1.25): P= 0.210) (Additional
file 8).
Also, the procedural success (as defined in the individ-
ual trials) was very similar in the study groups (94.6%
(90.8 to 97.5%) in the MAC group (193 of 205 patients)
and 96.4% (91.3 to 99.6%)) in the GA group (160 of 168
patients), (RR 0.98 (0.91 to 1.06); P =0.620) (Additional
file 9).
MAC was associated with a significantly shorter pro-
cedure time compared to GA, (MD −36 minutes, (−58.0
to −15.0 minutes); P <0.001) (Figure 4). There was con-
siderable heterogeneity among the trials with an I
2 of
97.4%.
Post-procedural outcome
On average, the stroke rate was 1.2% (0.1 to 3.3%) in the
MAC group (4 of 247 patients) and 3.8% (1.3 to 7.3%) in
the GA group (8 of 195 patients). Even though this
stroke rate was numerically lower in the MAC group, it
was not statistically significant (RR 0.50 (0.15 to 1.68);
P =0.460) (Figure 5).
The rate of myocardial infarction was not different be-
tween the study groups (2 of 247 patients in the MAC
and 1 in 195 patients in the GA group; RR 1.06 (0.20 to
5.54): P =0.950) (Additional file 10).
Post-interventional acute kidney injury did not differ
between the groups (28 of 247 patients in the MAC and
19 of 195 patients in the GA group; RR was 0.88 (0.50 to
1.55); P =0.650) (Additional file 11).
MAC was associated with significantly shorter hospi-
tal stay (MD −3.0 days (−4.99 to −0.96 days); P =0.004)
(Figure 6). There was considerable heterogeneity among
the trials with an I
2 of 88%.
The occurrence of peri-operative sepsis did not differ
significantly between the study groups (13 of 117 patients
in the MAC and 15 of 151 patients in the GA group; RR
1.23 (0.59 to 2.53); P=0.580) (Additional file 12).
Only one study reported on chest infections. Covello
et al. found a pneumonia rate of 8% after GA and 0%
after MAC.
Sensitivity analyses
We have repeated the key analyses excluding the study
of Linke et al. which has only been published as an ab-
stract [5]. Since this abstract contained limited informa-
tion it was only used for the calculation of the following
endpoints:
Procedure duration was reduced by 41 minutes (95%
CI 63 to 18 minutes; P <0.001] on average in the MAC
Study
Random effects model
Heterogeneity: I-squared = 14.3%, tau-squared = 0.1145, P = 0.3225
Yamamoto 2013
Motloch 2012
Dehedin 2011
Covello 2010
Ben-Dor 2012
Behan 2008
Total
326
130
41
34
42
70
9
Events
10
5
3
0
3
0
LA
Total
220
44
33
91
27
22
3
Events
3
3
6
0
4
1
GA
0.2 0.5 1 2 5
Risk Ratio
Favors LA       Favors GA
RR
0.77
1.13
1.34
1.34
0.65
0.24
0.12
95%-CI
[0.38 to  1.56]
[0.33 to  3.91]
[0.35 to  5.21]
[0.35 to  5.05]
[0.01 to 31.66]
[0.06 to  0.97]
[0.01 to  2.36]
Figure 2 Forest plot of risk ratios for 30-day mortality. Markers represent point estimates of risk ratios, marker size represents study weight in
random-effects meta-analysis. Horizontal bars indicate 95% confidence intervals. CI, confidence interval; RR, risk ratio.
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included). The duration of hospital stay was reduced by
3.8 days (5.3 to 2.3 days; P <0.001) with MAC (the re-
duction was 3.0 days, if Linke et al. was included).
Using the exact permutation test approach, the results
were nearly similar: the RR for mortality was 0.77 (0.37
to 1.60); P =0.656. The RR for cardiac and procedure-
related mortality was RR 0.90 (0.34 to 2.40); P =0.375.
For stroke, it was 0.50 (0.15 to 1.68); P =0.125. For vas-
cular complications, the RR was 0.66 (0.35 to 1.25):
P =0.500.
For sepsis, it was 1.23 (0.59 to 2.53); P= 0.500. For
myocardial infarction, it was 1.05 (0.20 to 5.54): P=
0.999. For acute kidney injury, the RR was 0.88 (0.50 to
1.55); P =0.875.
Further, we have excluded the very small study by Be-
han et al. The results were very similar: for mortality the
RR was 0.86 (0.43 to 1.70); P =0.662, for procedural car-
diac death, it was 0.96 (0.35 to 2.64); P =0.934.
Discussion
This is the first meta-analysis that compared the outcome
of MAC versus GA in patients undergoing transfemoral
TAVR. It is based on non-randomized data exclusively.
Mortality and safety endpoints did not significantly differ
between the two approaches. Procedural time and in-
hospital stay were significantly reduced with MAC. The
need for conversion from MAC to GA was infrequent.
Interestingly, the very first TAVR procedure, done over
a decade ago, was performed under MAC. With the de-
crease in sheath sizes and better closure devices, an in-
creasing number of operators might wish to switch to a
predominantly percutaneous approach under local anes-
thesia. Robust data on safety and risk of this approach
are therefore needed.
GA versus MAC
GA is generally the preferred option for patients un-
dergoing any major surgical interventions [28]. However,
GA itself carries a procedural mortality risk that aver-
ages 0.03 deaths per 1,000 patients, with even more of a
pronounced risk in open heart surgery and in a higher
risk population, such as the population currently consid-
ered for TAVR [29]. While this risk is clearly justified for
conventional cardiac surgery, its role can be challenged
for TAVR [27,30]. GA in patients with severe aortic sten-
osis may even be associated with a particularly increased
peri-procedural risk [31]. However, GA has certainly
multiple advantages for the operator:
 It enables real-time transesophageal echocardiography
(TEE) which might especially be helpful for
Study
Random effects model
Heterogeneity: I-squared = 16.8%, tau-squared = 0.0038, P = 0.3071
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[5.1 to 21.3%]
[3.0 to 48.2%]
Figure 3 Forest plot for conversion rate from MAC to GA. CI, confidence interval.
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Random effects model
Heterogeneity: I-squared = 97.4%, tau-squared = 556.8, P < 0.0001
Yamamoto
Motloch
Dehedin
Ben-Dor
Behan
Linke
Total
831
130
41
34
70
9
547
Mean
78.2
112.3
80.0
91.0
105.0
75.0
SD
30.90
4.90
26.00
56.30
25.93
40.00
Total
642
44
33
91
22
3
449
Mean
93.5
167.6
120.0
155.0
135.0
94.0
SD
26.9
5.2
37.0
89.0
89.0
47.0
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Mean difference
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MD
-36.34
-15.30
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-40.00
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Figure 4 Forest plot for procedural time (minutes). CI, confidence interval.
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prompt recognition of complications such as aortic
dissection, tamponade and valve embolization [32].
However, valve positioning is mainly guided by
fluoroscopy [33]. Echocardiography does not seem to
relevantly reduce contrast dye use. Two studies where
no TEE was used in the GA arm reported on contrast
dye use, and did not find a relevant difference [7,25].
Alternatively, intracardiac echocardiography, or even
transthoracic echocardiography could be used for
MAC. Furthermore, although rare,TEE itself can lead
to serious complications, such as esophageal
hematoma or rupture [34].
 GA may provide more stable conditions. Indeed,
it prevents the patient from moving, especially
during the critical phase of valve deployment
under rapid pacing. During this period with a
reduced cardiac output, patients with MAC might
become disorientated which may provoke
movements. On the other hand, our data show
that patients with GA were more likely to need
catecholamine support, as compared to MAC
[6]. Indeed, MAC can achieve similarly stable
conditions.
 GA allows a quick conversion to bail-out surgery in
case of peri-procedural complications. However, a
conversion to surgery is an infrequent event [6,7,26].
Furthermore, although only a few observational
studies report these data, conversion from MAC to
GA appears to be safe if operators are prepared for
this event. So far, there are no data indicating an
increased mortality risk after conversion from MAC
to GA [7,24-26].
MAC, on the other hand, has the advantage of shorter
procedure durations and a prompter recovery period
with shorter hospital stay [35]. A shorter hospital stay
decreases the risk for nosocomial infections and other
complications associated with a hospital stay [35]. In-
deed, nosocomial infection represents a significant prob-
lem; it is the eighth leading cause of death in the US
[36]. Moreover, mechanical ventilation is directly related
to an increased risk for pneumonia, especially in an eld-
erly population [37]. Infections should be avoided as far
Study
Random effects model
Heterogeneity: I-squared = 0%, tau-squared = 0, P = 0.9325
Yamamoto 2013
Motloch 2012
Dehedin 2011
Covello 2010
Total
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Figure 5 Forest plot of risk ratios (RR) for stroke. CI, confidence interval; RR, risk ratio.
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Figure 6 Forest plot for hospital stay (days). CI, confidence interval.
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thesis endocarditis [38].
Mortality and stroke rates were numerically lower for
MAC compared to GA, but this difference was not sta-
tistically significant. Whether this was due to a lack of
statistical power or whether these differences are indeed
simply a play of chance is unknown. We also have to
consider that the heterogeneous definitions for most
endpoints are a major limitation. Theoretically, MAC
may allow earlier recognition of complications compared
to non-responsive patients under GA (for example, stroke,
retroperitoneal bleed). GA may also result in pronounced
hypotension. Whether this would actually translate into
an earlier and more effective treatment and an improved
outcome remains speculative.
Notably, procedural time (predominantly defined as
the span of time between the patient entering until the
patient leaving the cath lab) and the total hospital stay
were significantly shorter for MAC. The difference in
procedural time was probably predominantly driven by
the additional need for anesthesia induction and wean-
ing/extubation after the procedure for patients undergo-
ing GA. For the patient, only the actual procedure time
really matters, but the total cath-lab time can have an
impact on resource use and costs. However, only one
study discriminated between total procedural time and
interventional time, both parameters were in favor of
MAC [6]. Interestingly, this study was the only one as-
sessing health economic aspects. The authors found a
63.4% reduction in cath-lab related costs with MAC [6].
This was mainly due to the reduced number of staff
needed and the shorter use of the cath-lab [6]. However,
we have to be aware that this was not a formal cost-
effectiveness analysis; it did not consider utility or the
costs beyond the staff costs related to the procedure
itself. Procedure-related costs account for only appro-
ximately 50% of the total costs for a TAVR procedure,
which is approximately €40,000 (approximately $53,400)
[39]. Some studies found a reduced need of “high de-
pendency care” after MAC [6,24-26]. Importantly, inten-
sive care stay is also a major contributor to health care
expenditure, especially if prolonged mechanical ventila-
tion is necessary [40]. Considering that our study did
not find relevant differences in outcomes and MAC is
likely to reduce the resource need, MAC may be the
overall cheaper option. However, this very much de-
pends on local factors and remains speculative at this
stage. A prospectively planned cost-effectiveness ana-
lysis, optimally linked to a randomized trial comparing
MAC versus GA would be needed to shed light on the
impact of MAC and GA on costs.
It is not clear why GA patients had longer hospital stays.
This may be due to a prolonged post-procedure recovery
period or simply due to differences in local protocols.
MAC appears to be safe and cost-effective and might
even yield an improved outcome after TAVR.
Outlook
We think that both approaches, MAC and LA, will have
a role in the future. In addition to the patient factors,
there will be center and operator experience and local
logistics which may play in the decision-making. Patient
factors need to be defined, those at high risk for GA (for
example, severe lung disease) may be better treated with
MAC. In particular, also, the patient preference for MAC
or GA will have to be taken into consideration. For now,
the decision should be made by a “heart team” which also
includes a cardiac anesthesiologist together with the
patient.
Limitations
This meta-analysis is based on seven non-randomized
studies exclusively. The results are therefore subject to
confounding factors, mainly based on a learning curve
effect, and the assignment to GA or MAC is often based
on patients’ co-morbidities.
Moreover, variations in the training might have had an
impact on the choice of anesthesia used, as Medtronic
encourages more MAC, compared to Edwards training,
which is in favor of GA.
One study retrieved data from the large CoreValve
ADVANCE registry [5]. These data were presented as an
abstract only but have not been published in the peer
reviewed literature so far. Most centers start a TAVR
program using GA and switch to MAC after they have
become experienced, which additionally contributes to
the heterogeneity of the studies. Most of the studies are
relatively small and the studies are rather heterogeneous,
which may generate false negative results. Interestingly,
in the CoreValve ADVANCE registry, which only in-
volves higher volume operators (>40 TAVRs), no mortal-
ity benefit was seen for MAC [41].
It is important to recognize that patients who are se-
lected for MAC were maybe chosen because they were
expected to be less at risk of technical complications or
in need for additional imaging, such as TEE? Although
the baseline characteristics of the two groups suggest
that they are similar in this aspect, certain indicators for
challenging procedures, such as aortic valve and root
anatomy, and others on the general condition of pa-
tients, such as frailty or immobilization, have not been
assessed in the analyzed studies. Therefore, there may be
a selection bias for MAC patients, which could not be
discriminated in this meta-analysis.
This was a study-level meta-analysis. An individual pa-
tient data analysis may provide further insights. End-
point definitions were not uniform, which contributes to
the heterogeneity among the different studies. Also, the
Fröhlich et al. BMC Medicine 2014, 12:41 Page 7 of 9
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widely among the included studies, which makes a uni-
form interpretation difficult. Indeed, only a large scale
randomized trial would be powered to allow for reliable
validation of MAC in TAVR.
Conclusions
The results of this meta-analysis demonstrate that there
is no significant difference in outcomes using either
MAC or GA for TAVR procedures. While GA can have
advantages, including improved peri-procedural imaging,
MAC may be associated with reduced procedural time
and shorter hospital stay. Randomized or large scale ob-
servational studies from national registries are now nee-
ded to identify those patients who may truly benefit from
this approach and to define the circumstances under
which it should be considered.
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